RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
  Constipation
  GERD
  IBS
  Inflammatory Bowel Disease
  Liver
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Jan 9, 2010 - 5:55:44 PM
Research Article
Gastroenterology Channel

subscribe to Gastroenterology newsletter
Latest Research : Gastroenterology

   EMAIL   |   PRINT
Naltrexone shown to help with Crohn's symptoms

Feb 2, 2007 - 11:49:11 AM , Reviewed by: Dr. Sanjukta Acharya
"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."

Key Points of this article
Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
Naltrexone shown to improve symptoms of patients with Crohn's disease.
 
[RxPG] A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.

A team of researchers led by gastroenterologist Jill P. Smith, M.D., and Ian S. Zagon, Ph.D., Distinguished Professor of neural and behavioral sciences, at the College of Medicine and Penn State Milton S. Hershey Medical Center, received NIH funding last summer to initiate a phase 2 trial of low-dose naltrexone and Crohn's.

In the pilot study, patients with diagnosed Crohn's disease were treated with a low dose of naltrexone and monitored for improvement of symptoms for 12 weeks. Quality of life surveys were given every four weeks for 16 weeks. The results, published this week, show that 89 percent of participants showed an improvement with therapy, while 67 percent achieved remission of symptoms. The only side effect to treatment was sleep disturbance in some patients.

Typical treatment for Crohn's involves using steroids or corticosteroids, which suppress the immune system and can have other toxic side effects. Treatment is often time-intensive and expensive, as well.

"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."





Publication: American Journal of Gastroenterology 

Funding information and declaration of competing interests: The phase 2 study of naltrexone for Crohn's is also supported by funding by the Broad Medical Research Program.

Related Gastroenterology News
Demographic profile suggests environmental role in etiology of Crohn's Disease
A novel and simple formula to predict treatment success in chronic hepatitis C
Fat in the liver -- not the belly -- is a better marker for disease risk
Sequential TACE and cryosurgery can improve survival times for patients with HCC?
Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine
No longer afraid to be a bridesmaid or travel with the boss
UIC researchers measure health effects of Chicago's waterways
Putting a name to the fluke
14.6% of patients with Iron deficiency anaemia of obscure origin have gluten sensitive enteropathy (GSE
Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial

Subscribe to Gastroenterology Newsletter

Enter your email address:


 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
 Additional information about the news article
In a related study, Smith and other College of Medicine researchers are studying the chemical and molecular mechanisms involved in suppression of inflammatory responses in the intestine when animals are treated with naltrexone.

Team members on the first study include Heather Stock, M.S.I.V., Sandra Bingaman, R.N. and David Mauger, Ph.D., Department of Health Evaluation Sciences, Penn State College of Medicine.

Members of the second study team include Gail L. Matters, Ph.D., and John F. Harms, Ph.D., Department of Biochemistry and Molecular Biology; Leo Fitzpatrick, Ph.D., Department of Surgery; and Anuj Parikh, B.S., and Nicholas Nilo, Department of Medicine, Penn State College of Medicine.


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

All rights reserved by RxPG
Contact Us